Al's Comment:

 Excellent review of all of the oncolytic viruses being used to treat Glioblastoma.  Of note is the Japan has given conditional time limited approval of one of them: teserpaturev, which is a small trial showed 92% 1 year survival for recurrent Glioblastoma which is unheard of!   Can't believe Japan implements conditional approvals and the USA doesn't yet!


Posted on: 06/01/2022

Clinical Trials of Oncolytic Viruses in Glioblastoma

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!